These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3629547)

  • 21. Pentoxifylline in end-stage renal disease.
    Silver MR; Kroboth PD
    Drug Intell Clin Pharm; 1987 Dec; 21(12):976-8. PubMed ID: 3428162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of pentoxifylline on experimental skin flap survival.
    Hodgson RS; Brummett RE; Cook TA
    Arch Otolaryngol Head Neck Surg; 1987 Sep; 113(9):950-2. PubMed ID: 3606845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of 3,7-dimethyl-1-(5-oxohexyl)-xanthine (pentoxifylline) and its 3,7-dimethyl-1-(5-hydroxyhexyl)-xanthine metabolite in the plasma of patients with multiple diseases using high-performance liquid chromatography.
    Rieck W; Platt D
    J Chromatogr; 1984 Feb; 305(2):419-27. PubMed ID: 6707169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of the potentiation of thrombolysis by pentoxifylline (Trental).
    Ambrus JL; Ambrus CM; Mahfzah M; Markus JA; Klein E; Gastpar H
    J Med; 1987; 18(5-6):265-76. PubMed ID: 3505256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [In vitro demonstration of hydroxylation of pentoxifylline].
    Poirier JM; Lebot M; Cheymol G
    Therapie; 1989; 44(1):69-70. PubMed ID: 2734726
    [No Abstract]   [Full Text] [Related]  

  • 26. Simultaneous determination of pentoxifylline and its hydroxy metabolite in plasma by high-performance liquid chromatography.
    Chivers DA; Birkett DJ; Miners JO
    J Chromatogr; 1981 Sep; 225(1):261-5. PubMed ID: 7298755
    [No Abstract]   [Full Text] [Related]  

  • 27. High-performance liquid chromatographic determination of pentoxifylline and its hydroxy metabolite in human plasma.
    Garnier-Moiroux A; Poirier JM; Cheymol G; Jaillon P
    J Chromatogr; 1987 Apr; 416(1):183-8. PubMed ID: 3597635
    [No Abstract]   [Full Text] [Related]  

  • 28. Interaction of pentoxifylline with human erythrocytes. II. Effects of pentoxifylline on the erythrocyte membrane.
    Sato Y; Miura T; Suzuki Y
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):555-8. PubMed ID: 2337973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of pentoxifylline and its 5-hydroxy metabolite in human plasma by solid-phase extraction and high-performance liquid chromatography with ultraviolet detection.
    Musch G; Hamoir T; Massart DL
    J Chromatogr; 1989 Oct; 495():215-26. PubMed ID: 2613806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-response effects of pentoxifylline on erythrocyte filterability: clinical and animal model studies.
    Ambrus JL; Anain JM; Anain SM; Anain PM; Anain JM; Stadler S; Mitchell P; Brobst JA; Cobert BL; Savitsky JP
    Clin Pharmacol Ther; 1990 Jul; 48(1):50-6. PubMed ID: 2196145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of orally administered pentoxifylline in humans.
    Smith RV; Waller ES; Doluisio JT; Bauza MT; Puri SK; Ho I; Lassman HB
    J Pharm Sci; 1986 Jan; 75(1):47-52. PubMed ID: 3958905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microbial models of mammalian metabolism: stereospecificity of ketone reduction with pentoxifylline.
    Davis PJ; Yang SK; Smith RV
    Xenobiotica; 1985 Dec; 15(12):1001-10. PubMed ID: 3911603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of pentoxifylline with human erythrocytes. I. Interaction of xanthine derivatives with human erythrocyte ghosts.
    Sato Y; Miura T; Suzuki Y
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):552-4. PubMed ID: 2337972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetics of intravenous and oral pentoxifylline in healthy subjects.
    Beermann B; Ings R; Månsby J; Chamberlain J; McDonald A
    Clin Pharmacol Ther; 1985 Jan; 37(1):25-8. PubMed ID: 3965236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of pulmonary hypoxic vasoconstriction with pentoxifylline and aminophylline in isolated lungs.
    Hakim TS
    Can J Physiol Pharmacol; 1988 Feb; 66(2):146-51. PubMed ID: 3370545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition cAMP-phosphodiesterase in the rat heart by pentoxifylline--a new xanthine derivative.
    Nandi JS; Nair KG; Deo S
    Adv Myocardiol; 1980; 1():359-65. PubMed ID: 6248939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of pentoxifylline on the flow of polymorphonuclear leukocytes through a model capillary.
    Armstrong M; Needham D; Hatchell DL; Nunn RS
    Angiology; 1990 Apr; 41(4):253-62. PubMed ID: 2339824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update on the pharmacology of pentoxifylline and its combination with low-dose acetylsalicylic acid (HWA 5112).
    Seiffge D; Weithmann KU
    Semin Thromb Hemost; 1989 Apr; 15(2):150-8. PubMed ID: 2749263
    [No Abstract]   [Full Text] [Related]  

  • 39. In vitro effects of pentoxifylline on hemoglobin affinity for oxygen and electrolytic equilibrium of human blood.
    Ferraresi I; Bozzini F; Torta D; Frigerio R; Bernasconi C; Agostoni A
    Ric Clin Lab; 1983; 13(4):459-65. PubMed ID: 6658304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of phenol ring polymers on the release of plasminogen activators].
    Klöcking HP; Klöcking R; Helbig B
    Farmakol Toksikol; 1984; 47(1):93-5. PubMed ID: 6538511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.